We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know
Read MoreHide Full Article
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $162.84, marking a +0.02% move from the previous day. This change lagged the S&P 500's 0.64% gain on the day. Elsewhere, the Dow saw an upswing of 0.85%, while the tech-heavy Nasdaq appreciated by 0.31%.
Shares of the world's biggest maker of health care products witnessed a gain of 4.27% over the previous month, beating the performance of the Medical sector with its loss of 0.88% and the S&P 500's loss of 7.69%.
Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company plans to announce its earnings on April 15, 2025. The company's upcoming EPS is projected at $2.59, signifying a 4.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.66 billion, up 1.29% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $10.58 per share and revenue of $90.03 billion, which would represent changes of +6.01% and +1.36%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Johnson & Johnson is currently a Zacks Rank #3 (Hold).
Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 15.38. This denotes a premium relative to the industry's average Forward P/E of 14.59.
Also, we should mention that JNJ has a PEG ratio of 2.61. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.31 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 70, this industry ranks in the top 28% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $162.84, marking a +0.02% move from the previous day. This change lagged the S&P 500's 0.64% gain on the day. Elsewhere, the Dow saw an upswing of 0.85%, while the tech-heavy Nasdaq appreciated by 0.31%.
Shares of the world's biggest maker of health care products witnessed a gain of 4.27% over the previous month, beating the performance of the Medical sector with its loss of 0.88% and the S&P 500's loss of 7.69%.
Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company plans to announce its earnings on April 15, 2025. The company's upcoming EPS is projected at $2.59, signifying a 4.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.66 billion, up 1.29% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $10.58 per share and revenue of $90.03 billion, which would represent changes of +6.01% and +1.36%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Johnson & Johnson is currently a Zacks Rank #3 (Hold).
Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 15.38. This denotes a premium relative to the industry's average Forward P/E of 14.59.
Also, we should mention that JNJ has a PEG ratio of 2.61. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.31 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 70, this industry ranks in the top 28% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.